849146



SEC 1972 Potential persons who are to respond to the collection

a this

(6-02) form are not required to respond unless the form displays a currently valid OMB control number.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption state exemption unless such exemption is predicated on the filing of a federal notice.

JAN 1 3 ZUUS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

PROCESSED

JAN 14 2005 E

(Including Area Code)

(if different from Executive Offices)

FORM D

THOMS POTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

Address of Principal Business Operations (Number and Street, City, State, Zip Code)

same

OMB APPROVAL	1
OMB Number: 3235-0076	
Expires: May 31, 2005	-
Estimated average burden	
hours per response 1	į

SEC USE ONLY

DATE RECEIVED

Telephone Number

Serial

Prefix

Name of Offering ([] check if this is an amendment and name has changed, and indicate change.) Lifeline Therapeutics, Inc. Filing Under (Check box(es) that [] Rule 504 [] Rule 505 [] Rule 506 [X] Section 4(6) [] ULOE apply): Type of Filing: [X] New Filing [] Amendment A. BASIC IDENTIFICATION DATA 1. Enter the information requested about the issuer Name of Issuer ([] check if this is an amendment and name has changed, and indicate change.) Lifeline Therapeutics, Inc. Address of Executive Offices (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code) 6400 South Fiddlers Green Circle, Suite 1750, Englewood CO 80111 720 488 1711

h

Brief Description of Busine life expectancy.	ess: Manufacturing, marketing and distribution of therapies promoting healthy
Type of Business Organiz	ation
[X] corporation	[] limited partnership, already formed [] other (please specify):
[] business trust	[] limited partnership, to be formed
	Month Year of Incorporation or Organization: [0][6] [8][8] [X] Actual [] Estimated on or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction) [C][O]
GENERAL INSTRUCTION Federal:	NS
	making an offering of securities in reliance on an exemption under Requisition D or 501 et seq. or 15 U.S.C. 77d(6).
is deemed filed with the U by the SEC at the address	st be filed no later than 15 days after the first sale of securities in the offering. A notice .S. Securities and Exchange Commission (SEC) on the earlier of the date it is received given below or, if received at that address after the date on which it is due, on the ed States registered or certified mail to that address.
Where to File: U.S. Securi	ties and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.
	copies of this notice must be filed with the SEC, one of which must be manually inually signed must be photocopies of manually signed copy or bear typed or printed
name of the issuer and off	ew filing must contain all information requested. Amendments need only report the ening, any changes thereto, the information requested in Part C, and any material ion previously supplied in Parts A and B. Part E and the Appendix need not be filed
Filing Fee: There is no fed	eral filing fee.
State:	
securities in those states t must file a separate notice made. If a state requires the	o indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of hat have adopted ULOE and that have adopted this form. Issuers relying on ULOE with the Securities Administrator in each state where sales are to be, or have been ne payment of a fee as a precondition to the claim for the exemption, a fee in the npany this form. This notice shall be filed in the appropriate states in accordance with

state law. The Appendix in the notice constitutes a part of this notice and must be completed.

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;

- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

Check Box(es) that Apply:	[] Promoter [X] Beneficial Owner	[X] Executive Officer	[X] Director [] General and/or Managing Partner
Full Name (Last nam	ne first, if individual) Driscoll, W	/illiam Joseph (Ros	semary A. is joint owner)
	ce Address (Number and Stree a Street, Englewood, Colorad		de)
Check Box(es) that Apply:	[] Promoter [X] Beneficial Owner	[X] Executive Officer	[X] Director [] General and/or Managing Partner
Full Name (Last nam	ne first, if individual) Streets, D	aniel W. (Carol H. i	s joint owner)
	ce Address (Number and Stree Drive, Aurora, Colorado 8016		de)
Check Box(es) that Apply:	[] Promoter [X] Beneficial Owner	[X] Executive Officer	[X] Director [] General and/or Managing Partner
Full Name (Last nam	ne first, if individual) Myhill, Pa	ul Robert (Lisa Gai	l is joint owner)
	ce Address (Number and Street urt, Castle Rock, Colorado 80°		de)
Check Box(es) that Apply:	[] Promoter [X] Beneficial Owner	[] Executive Officer	[] Director [] General and/or Managing Partner
Full Name (Last nam	ne first, if individual) McCord, J	loe	······································
	ce Address (Number and Street Street, Unit 6, Denver, Colora		de)
Check Box(es) that Apply:	[] Promoter [] Beneficial Owner	[] Executive Officer	[X] Director [] General and/or Managing Partner
Full Name (Last nam	ne first, if individual) Micklatch	er, Christopher Jor	ge
Business or Residen 10829 North 43 rd St	ce Address (Number and Street reet, Augusta, MI 49012	t, City, State, Zip Co	de)
(Use bl	lank sheet, or copy and use a	dditional copies of	this sheet, as necessary.)

B. INFORMATION ABOUT OFFER	ING	
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited offering?	I investors in this	Yes No [] [x]
Answer also in Appendix, Column 2, if filing und	ler ULOE.	
2. What is the minimum investment that will be accepted from any individ	ual?	. \$25,000
3. Does the offering permit joint ownership of a single unit?	······································	Yes No [x][]
4. Enter the information requested for each person who has been or will or indirectly, any commission or similar remuneration for solicitation of puwith sales of securities in the offering. If a person to be listed is an associated proker or dealer registered with the SEC and/or with a state or states, list or dealer. If more than five (5) persons to be listed are associated person dealer, you may set forth the information for that broker or dealer only. N/A	rchasers in conne lated person or ag the name of the b	ection ent of a proker
		······································
Full Name (Last name first, if individual)		
Business or Residence Address (Number and Street, City, State, Zip Coo	de)	
Name of Associated Broker or Dealer		
States in Which Person Listed Has Solicited or Intends to Solicit Purchas	ers	······································
(Check "All States" or check individual States)		
C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSE	S AND USE OF F	PROCEEDS
1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box " and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
Towns of One of the	Aggregate	Amount Already
Type of Security Debt	Offering Price	Sold
Equity	\$ \$	\$ @
[] Common [] Preferred	Ψ	Ψ
Convertible Securities (including warrants)	\$ 1,255,000*	\$ 255,000
Partnership Interests	\$-0-	\$-0-
Other (Specify).	\$	\$
Total	\$ 1,255,000+	\$ 255,000
Answer also in Appendix, Column 3, if filing under ULOE.		
* Does not include shares that may be acquired by investors if they choose to convert their investments into the Private Placement or the warrants attached to their investment. The conversion price and the exercise price of the attached warrants cannot be determined until the		
Private Placement share price is determined.		
+ Does not include the proceeds from the exercise of common stock		

amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
N/A	Number Investors	Aggregate Dollar Amount of Purchases
Accredited Investors		_\$
Non-accredited Investors		\$
Total (for filings under Rule 504 only)		\$ <u>-0-</u>
Answer also in Appendix, Column 4, if filing under ULOE.		
3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C-Question 1.	·	
N/A		
Type of offering	Type of Security	Dollar Amount Sold
Rule 505		\$
Regulation A		\$
Rule 504		. \$
Total	-0-	\$ <u>-0-</u>
4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
Transfer Agent's Fees		[] \$
Printing and Engraving Costs Legal Fees Accounting Fees Engineering Fees		[] \$ [] \$500.00 [] \$ [] \$
Sales Commissions (specify finders' fees separately)		[]\$
Other Expenses (identify)		[]\$
Total		[0]\$500.00
i Otai	•••••	[0] \$ 000.00
b. Enter the difference between the aggregate offering price given in resp Question 1 and total expenses furnished in response to Part C - Question the "adjusted gross proceeds to the issuer."	4.a. This differen	
	<u>\$</u> 1,254,500*	+
* Does not include shares that may be acquired by investors if they cho investments into the Private Placement or the warrants attached to the		

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar

conversion price and the exercise price of the attached warrants cannot be determined until the Private Placement share price is determined.

+ Does not include the proceeds from the exercise of common stock

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.

	Payments to Officers,	<u>.</u>
	Directors, & Affiliates	Payments To Others
Salaries and fees	[X]\$ 200,000	[X] \$
Purchase of real estate	[X]\$	[X]\$
Purchase, rental or leasing and installation of machinery and equipment	[X]\$	[X] \$
Construction or leasing of plant buildings and facilities	[X] \$	[X]\$
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	[X]\$	[X]\$
Repayment of indebtedness	[X] \$	[X] \$
Working capital	[X] \$ 1,054,500	[X]\$
Other (specify):	[X] \$	[X] \$
Column Totals	[X] \$ 1,254,500	[X] \$ [X] \$
Total Payments Listed (column totals added)		[X]\$1,254,500

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under <u>Rule 505</u>, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type)	Signature	Date
Lifeline Therapeutics, Inc.	William Dr	usive 01/10/05
Name of Signer (Print or Type) William Joseph Driscoll	Title of Signer (Print or 1 President	Fype)
	ATTENTION	

Intentional misstatements or omissions of fact constitute federal criminal violations.	(See	18 U.S.C
1001.)		

E. S	TAT	'E SI	GN.	ΑTI	JRE
------	-----	-------	-----	-----	-----

Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?	Yes No [] [X]"

See Appendix, Column 5, for state response.

- 2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239,500) at such times as required by state law.
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type)	Signature	Date
Lifeline Therapeutics, Inc.	000000	01/10/05
Name of Signer (Print or Type)	Title (Print or Type)	
William Joseph Driscoll	President	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.